| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg | |||
| Other Sizes |
| Targets |
Gelsevirine targets STING (stimulator of interferon genes), a key signaling molecule in the innate immune response. The compound also acts as an agonist of brain glycine receptors, which may be involved in its anxiolytic mechanism. Gelsevirine modulates central nervous system signaling and exhibits antiproliferative activity against cancer cells. Its multiple targets make it a valuable molecule for exploring therapeutic mechanisms in inflammation, anxiety, and cancer.
|
|---|---|
| ln Vitro |
Gelsevirine demonstrates potent antiproliferative activity against MGC80-3 and SW480 cells with IC50 values of 1.41 mM and 1.22 mM, respectively. It inhibits interferon and inflammatory cytokine induction in macrophages exposed to STING agonists. The compound exhibits anxiolytic effects through glycine receptor agonism. These in vitro findings support its potential applications in inflammation research, cancer research, and neuropharmacology.
|
| ln Vivo |
Gelsevirine has been studied for its analgesic, anti-inflammatory, and neuroactive properties in vivo. The compound attenuates STING-related inflammation in sepsis models. Its anxiolytic effects, mediated through glycine receptor agonism, suggest potential for in vivo evaluation in anxiety-related disorders. The compound has been investigated as a potential treatment for anxiety-related disorders in human patients. However, comprehensive in vivo studies are limited, and the compound is intended for research use only.
|
| Enzyme Assay |
In vitro receptor binding assays for Gelsevirine typically involve testing its activity at the glycine receptor. Receptor activation is assessed using electrophysiological methods or calcium imaging in cells expressing glycine receptors. STING inhibition is evaluated in macrophage cell lines by measuring interferon and inflammatory cytokine production following STING agonist stimulation. Antiproliferative activity is assessed using cell viability assays in cancer cell lines such as MGC80-3 and SW480, with IC50 values determined from dose-response curves.
|
| Cell Assay |
In vitro cell-based assays for Gelsevirine involve culturing macrophages to evaluate its effects on STING-mediated inflammation. Cells are treated with varying concentrations of the compound and stimulated with STING agonists; interferon and inflammatory cytokine levels are measured by ELISA. For antiproliferative studies, cancer cell lines such as MGC80-3 and SW480 are treated with the compound and cell viability is assessed using MTT or similar assays. Cell viability is assessed to ensure observed effects are not due to cytotoxicity. All experiments are performed with appropriate controls.
|
| Animal Protocol |
In vivo animal experiments for Gelsevirine have been conducted in sepsis models to evaluate its effects on STING-related inflammation. Animals are administered the compound and inflammatory markers are measured. For anxiolytic studies, animal models of anxiety would be used to assess behavioral effects. Parameters assessed would include inflammatory cytokine levels, behavioral outcomes, and tissue histopathology. Control groups receiving vehicle alone would be included for comparison. All procedures would comply with institutional animal care and use committee guidelines.
|
| ADME/Pharmacokinetics |
The pharmacokinetic properties of Gelsevirine reflect its nature as an alkaloid. It has a molecular weight of 352.43 and the molecular formula C21H24N2O3. As a lipophilic alkaloid, it can cross the blood-brain barrier, which is relevant for its anxiolytic and neuroactive effects. The compound is expected to be metabolized through standard xenobiotic pathways in the liver. Complete pharmacokinetic profiling including half-life, clearance, volume of distribution, and bioavailability would require further systematic studies using appropriate analytical methods such as high-performance liquid chromatography-mass spectrometry.
|
| Toxicity/Toxicokinetics |
The toxicity profile of Gelsevirine has been evaluated in the context of its use as a research chemical. As a major alkaloid from Gelsemium elegans, which is known to be toxic, the compound should be handled with caution. Proper handling procedures including use of personal protective equipment are recommended when working with the compound. The compound is not approved for human therapeutic use and is intended for research purposes only. Long-term toxicity studies would be needed to fully establish its safety profile.
|
| References |
|
| Additional Infomation |
Reports indicate that gelsevirine has been found in Gelsemium rankinii, Gelsemium elegans, and Gelsemium sempervirens, and relevant data are available for reference.
Gelsevirine (CAS# 38990-03-3) has the molecular formula C21H24N2O3 and a molecular weight of 352.43. The compound is the major alkaloid in Gelsemium elegans with potent anxiolytic effects. Gelsevirine is a novel STING-specific inhibitor that attenuates STING-related inflammation in sepsis. It exhibits antiproliferative activity against MGC80-3 and SW480 cells and has been studied for analgesic, anti-inflammatory, and neuroactive properties. |
| Molecular Formula |
C21H24N2O3
|
|---|---|
| Molecular Weight |
352.43
|
| Exact Mass |
352.178
|
| CAS # |
38990-03-3
|
| PubChem CID |
14217344
|
| Appearance |
Off-white to light yellow solid
|
| Density |
1.3±0.1 g/cm3
|
| Boiling Point |
456.6±55.0 °C at 760 mmHg
|
| Melting Point |
245 °C
|
| Flash Point |
229.9±31.5 °C
|
| Vapour Pressure |
0.0±1.1 mmHg at 25°C
|
| Index of Refraction |
1.662
|
| Source |
Originated from plants: Loganiaceae Gelsemium eleganis (Gardn. et Champ.) Benth.
|
| LogP |
2.74
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
26
|
| Complexity |
682
|
| Defined Atom Stereocenter Count |
7
|
| SMILES |
O1C([H])([H])[C@]2([H])[C@]3([H])[C@]4([H])[C@@]5(C(N(C6=C([H])C([H])=C([H])C([H])=C56)OC([H])([H])[H])=O)[C@]1([H])C([H])([H])[C@@]2([H])[C@]4(C([H])=C([H])[H])C([H])([H])N3C([H])([H])[H]
|
| InChi Key |
SSSCMFCWHWCCEH-LGUFPRDESA-N
|
| InChi Code |
InChI=1S/C21H24N2O3/c1-4-20-11-22(2)17-12-10-26-16(9-14(12)20)21(18(17)20)13-7-5-6-8-15(13)23(25-3)19(21)24/h4-8,12,14,16-18H,1,9-11H2,2-3H3/t12?,14-,16+,17-,18+,20?,21+/m1/s1
|
| Chemical Name |
(1R,5S,6S,7S,8S)-2-ethenyl-1'-methoxy-4-methylspiro[9-oxa-4-azatetracyclo[6.3.1.02,6.05,11]dodecane-7,3'-indole]-2'-one
|
| Synonyms |
Gelsevirine
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: ~100 mg/mL (~283.7 mM; with ultrasonication)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (7.09 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), Clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (25.0 mg/mL) to 400 μL of PEG300 and mix well; then add 50 μL of Tween-80 and mix well; finally add 450 μL of physiological saline and adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 2.5 mg/mL (7.09 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), Suspended solution; with ultrasonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (25.0 mg/mL) to 900 μL of 20% SBE-β-CD saline and mix well. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 3: ≥ 2.5 mg/mL (7.09 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), Clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (25.0 mg/mL) to 900 μL of corn oil and mix well. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.8374 mL | 14.1872 mL | 28.3744 mL | |
| 5 mM | 0.5675 mL | 2.8374 mL | 5.6749 mL | |
| 10 mM | 0.2837 mL | 1.4187 mL | 2.8374 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
